Compound Summary
Compound Information
Amuvatinib
Compound Name: | Amuvatinib |
Compound CID: | 11282283 |
Synonyms: | Amuvatinib 850879-09-3 MP-470 MP470 MP 470 More... |
Iupac Name: | N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide |
InChI: | InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32) |
InChIKey: | FOFDIMHVKGYHRU-UHFFFAOYSA-N |
Canonical Smiles: | C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6 |
Isomeric Smiles: | C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6 |
Molecular Weight: | 447.5 |
Molecular Formula: | C23H21N5O3S |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Amuvatinib
Molecular Weight: | 447.5 |
Molecular Formula: | C23H21N5O3S |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 7 |
Rotatable Bond Count: | 3 |
Heavy Atom Count: | 32 |
Complexity: | 678 |
Synonyms
Amuvatinib
| Amuvatinib | Amuvatinib |
|---|---|
Amuvatinib |
850879-09-3 |
MP-470 |
MP470 |
MP 470 |
HPK56 |
HPK 56 |
Amuvatinib (MP-470) |
UNII-SO9S6QZB4R |
HPK-56 |
N-(benzod1,3dioxol-5-ylmethyl)-4-(benzofuro3,2-dpyrimidin-4-yl)piperazine-1-carbothioamide |
Amuvatinib (MP-470, HPK 56) |
SO9S6QZB4R |
N-(1,3-benzodioxol-5-ylmethyl)-4-(1benzofuro3,2-dpyrimidin-4-yl)piperazine-1-carbothioamide |
N-(Benzod1,3dioxol-5-ylmethyl)-4-(benzofuro-3,2-dpyrimidin-4-yl)piperazine-1-carbothioamide |
N-(benzod1,3dioxol-5-ylmethyl)-4-(benzofuro3,2-dpyrimidin-4-yl)piperazine-1-carbothioamide. |
Amuvatinib USAN:INN |
1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-d)pyrimidin-4-yl- |
1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro3,2-dpyrimidin-4-yl- |
Amuvatinib(MP470) |
Amuvatinib (USAN/INN) |
SCHEMBL93976 |
cc-525 |
MLS006010954 |
GTPL7932 |
CHEMBL2103851 |
CHEBI:91389 |
DTXSID50234176 |
EX-A236 |
SYN1056 |
BCPP000157 |
HMS3244A11 |
HMS3244A12 |
HMS3244B11 |
HMS3295E01 |
HMS3654D07 |
MP-470 (RAD51) |
BDBM50172081 |
MFCD16038298 |
NSC754349 |
NSC799332 |
s1244 |
ZINC34951302 |
AKOS025149102 |
BCP9000965 |
CCG-264877 |
CS-0178 |
DB12742 |
NSC-754349 |
NSC-799332 |
QC-8281 |
SB19384 |
N-(1,3-Benzodioxol-5-ylmethyl)-4-benzofuro3,2-dpyrimidin-4-yl-1-piperazinecarbothioamide |
NCGC00263158-01 |
NCGC00263158-07 |
AC-32058 |
AS-16213 |
HY-10206 |
N-(1,3-Benzodioxol-5-ylmethyl)-4-(benzofuro(3,2-d)pyrimidin-4-yl)piperazine-1- carbothioamide |
SMR004702758 |
AB0008091 |
FT-0717843 |
SW219808-1 |
X7485 |
D09864 |
879B093 |
J-523155 |
BRD-K66538826-001-01-5 |
Q27074458 |
4-Benzo4,5furo3,2-dpyrimidin-4-yl-piperazine-1-carbothioic acid (benzo1,3-dioxol-5-ylmethyl)-amide |
4-Benzo4,5furo3,2-dpyrimidin-4-yl-piperazine-1-carbothioic acid (benzo1,3dioxol-5-ylmethyl)-amide |
4-Benzo4,5furo3,2-dpyrimidin-4-yl-piperazine-1-carbothioic acid(benzo1,3dioxol-5-ylmethyl)-amide |
4-Benzo4.5furo3.2-dpyrimidin-4-yl-piperazine-1-carbothioic acid (benzo1.3dioxol-5-ylmethyl)-amide |
N-(1,3-benzodioxol-5-ylmethyl)-4-(1benzoxolo2,3-epyrimidin-4-yl)piperazine-1-carbothioamide |
Experimental Data
Amuvatinib
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 10 | umol/L | 0 | S | N2 | 32735859 | Active | ||||||
| Caenorhabditis elegans | 5 | umol/L | 0 | NS | N2 | 32735859 | Inactive | ||||||
| Caenorhabditis elegans | 20 | umol/L | 0 | NS | N2 | 32735859 | Inactive | ||||||
| Caenorhabditis elegans | 2.5 | umol/L | 0 | NS | N2 | 32735859 | Inactive |
Experimental Data Visualization
Amuvatinib
Statistics Data
Amuvatinib
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 0 | 1 | 4 |
Statistics Data Visualization
Amuvatinib
